Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2007-03-20
2007-03-20
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S024300, C536S024310
Reexamination Certificate
active
09724841
ABSTRACT:
Nucleic acid sequences which encode biologically active ETF, expression vectors which direct the expression of ETF, ETF polypeptides, antibodies which specifically bind ETF and processes for preparing the same are disclosed. Also disclosed are methods for treating or preventing gastrointestinal diseases and HIV or HIV-associated diseases.
REFERENCES:
patent: 5552303 (1996-09-01), Grabstein et al.
patent: 5574138 (1996-11-01), Grabstein et al.
patent: 5707616 (1998-01-01), Grabstein et al.
patent: 5795966 (1998-08-01), Grabstein et al.
patent: 5874566 (1999-02-01), Veerapanane et al.
patent: 5892001 (1999-04-01), Grabstein et al.
patent: 5985262 (1999-11-01), Grabstein et al.
patent: 5985663 (1999-11-01), Bennett et al.
patent: 6013480 (2000-01-01), Grabstein et al.
patent: 6087172 (2000-07-01), Veerapaneni et al.
patent: 6165466 (2000-12-01), Grabstein et al.
patent: 6168783 (2001-01-01), Grabstein et al.
patent: 6177079 (2001-01-01), Grabstein et al.
patent: 6184359 (2001-02-01), Gabstein et al.
patent: 6344192 (2002-02-01), Grooten et al.
patent: 2002/0082230 (2002-06-01), Douvdevani et al.
Smith et al. (1991) The EMBO Journal. vol. 10, No. 8, pp. 2223-2230.
David E. Kennell (1971) Progr. Nucl. Acid Res. Mol. Biol. 11, pp. 259-301.
Armitage et al., “IL-15 HAS Stimulatory Activity for the Induction of B Cell Proliferation and Differentiation,”The Journal of Immunology154:483-490, 1995.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science247:1306-1310, 1990.
Callard and Gearing,The Cytokine FactsBook, Academic Press, San Diego, CA 1994, 39-40.
Carson et al., “Interleukin (IL) 15 is a Novel Cytokine that Activates Human Natural Killer Cells via Components of the IL-2 Receptor,”J. Exp. Med., 180:1395-1403, 1994.
Coleman et al., “Characterization of a Keratinocyte-Derived T Cell Growth Factor Distinct from Interleukin2 and B Cell Stimulatory Factor 11,”The Journal of Immunology138:3314-3318, 1987.
Cornaglia-Ferris and Ponzoni,, “T Cells from Lymphoepithelial Thymoma Produce a Biochemical Variant of IL-2,”Lymphokine Research4(3):P 251-263, 1985.
Giri et al., “Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15,”The EMBO Journal13(12):2822-2830, 1994.
Grabstein et al., “Cloning of a T Cell Growth Factor that Interacts with the β Chain of the Interleukin-2 Receptor,”Science264:965-968, 1994.
Lerner, “Tapping the immunological repertoire to produce antibodies of predetermined specificity,”Nature299:592-596, 1982.
McMahan et al., “A novel IL-1 receptor, cloned from B cells by mammalian expression, is expressed in many cell types.”The EMBO Journal1010):2821-2832, 1991.
Nishimura et al., “Site-specific mutagenesis of human interleukin-6 and its biological activity,”FEBS281(1,2):167-169, 1991.
Ogata et al., “Capacities of a Newly Established Thymic Stromal Cell Clone to Express la Antigens and to Produce Interleukin-6, Colony-Stimulating Factor, and Thymic Stroma-Derived T-Cell Growth Factor,”Journal of Leukocyte Biology45:69-78, 1989.
Sevier et al., “Monoclonal Antibodies in Clinical Immunology,”Clinical Chemistry27(11):1797-1806, 1981.
Shimamura et al., “Analysis of Interleukin6 (IL-6)/IL-6 Receptor System Using Monoclonal Anti-IL6 Antibodies,”Molecular Immunology28(11):1155-1161, 1991.
Tinubu et al., “Humanized Antibody Directed to the IL-2 Receptor β-Chain Prolongs Primate Cardiac Allograft Survival,”The Journal of Immunology153:4330-4338, 1994.
Anderson Dirk M.
Eisenman June R.
Fung Victor
Grabstein Kenneth H.
Rauch Charles
Amgen Inc.
Davis , Wright, Tremaine, LLP
Mertz Prema
Potter Jane E. R.
LandOfFree
Polynucleotides encoding epithelium-derived T-cell factor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding epithelium-derived T-cell factor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding epithelium-derived T-cell factor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3805870